Join
Live feed
·
INSIDERFilingvia Quantisnow
Arrowhead Pharmaceuticals Inc. logo

Chief Financial Officer Apel Daniel Joseph sold $934,285 worth of shares (13,095 units at $71.35) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 162,905 units (SEC Form 4) (withholding obligation)

ByQuantisnow·Wall Street's wire, on your screen.
ARWR· Arrowhead Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARWR (Arrowhead Pharmaceuticals Inc.) and more on Quantisnow.